Medical Devices; General Hospital and Personal Use Devices; Classification of the Active Noise Attenuation System for Infant Incubators
What happened
The Food and Drug Administration (FDA) is classifying the active noise attenuation system for infant incubators into class II (special controls). This action, signed by Donald Trump, ensures reasonable assurance of safety and effectiveness, and reduces regulatory burdens. This order is effective July 27, 2026, though the classification was applicable on June 16, 2023. This decision resulted from a De Novo classification request from Invictus Medical, Inc. on July 25, 2022, for their Neoasis device.
Why it matters
This classification into Class II, with special controls, aims to enhance patient access to beneficial innovative medical devices by potentially lowering regulatory hurdles. The FDA believes this action strikes a balance between ensuring device safety and encouraging new medical technology development.
Who it affects
- ›Infants in incubators
- ›Hospitals and healthcare facilities
- ›Medical device manufacturers like Invictus Medical, Inc.
- ›Companies developing similar noise attenuation systems
- ›The Food and Drug Administration (FDA)
The receipts are official. The summary is ours.
Read on Federal Register ↗Summaries are generated from the official text and may simplify or omit nuance. The official document is the source of truth.